ASH 2018 | Monoallelic TP53-mutated CLL patients show durable response to ibrutinib monotherapy
Carsten Niemann
• 2 Dec 2018
Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, describes how a recent study found chronic lymphocytic leukemia (CLL) patients responded better to ibrutinib monotherapy if they only had a monoallelic TP53 aberration, compared to those with biallelic. Monoallelic TP53-mutated patients had better progression-free survival compared to biallelic patients. This knowledge has the potential to identify patients who would benefit from single-agent ibrutinib therapy and those who would not. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
